NCT06485245View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 22, 2025

Primary Completion Date

November 20, 2025

Study Completion Date

December 18, 2025

Conditions
MASH
Interventions
DRUG

CS060304

Tablets administered orally

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Cascade Pharmaceuticals, Inc

OTHER

NCT06485245 - Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects | Biotech Hunter | Biotech Hunter